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Abstract
Chromosome 22q11.2 deletion syndrome (22q11.2DS) results from a hemizygous
deletion located on the long arm of chromosome 22. The most common deletion sizes affect
between 30 and 90 genes. Individuals with 22q11.2DS may develop serious developmental and
psychiatric disorders. The phenotype is highly variable, however, and may be influenced by
allelic variation of the retained copies of genes covered by the deletion. I set out to examine the
effects of two genes, catechol-O-methyltransferase (COMT) and proline dehydrogenase
(PRODH), in relation to anxiety in children and adolescents with 22q11.2DS. Individuals with
the major COMT allele (higher activity) have significantly higher anxiety than those with the
minor allele (p=0.021). Analyses of endocrine indicators of stress suggested that individuals
with the minor COMT allele may have higher levels of salivary DHEA and alpha amylase
associated with dysregulation of the hormonal stress-response system, though these results
were not significant after a Bonferroni correction.

Keywords: 22q11.2DS, Anxiety, DiGeorge Syndrome, Neurodevelopmental disorder, Genetics,
Velocardiofacial Syndrome

viii

Background
Overview
Chromosome 22q11.2 deletion syndrome (22q11.2DS) is the most commonly occurring
genetic microdeletion in humans (Bertini et al., 2019; Du et al., 2020; Hwang et al., 2014;
Morrow et al., 2018; Robin & Shprintzen, 2005). Identifying biomarkers of risk and
understanding the endophenotype, a psychiatric concept that connects a genetic aspect to a
behavioral/psychological/physiological symptom, can allow for monitoring and potential
intervention to reduce the risk of serious mental illness later. 22q11.2DS is a
neurodevelopmental syndrome for understanding both rare and frequent medical conditions
that are associated with congenital anomalies, including psychiatric and developmental
disorders (McDonald-McGinn et al., 2015). Along with helping individuals affected by
22q11.2DS, information obtained from studying the condition will assist in providing a more
inclusive understanding of other genetic disorders, leading to earlier diagnosis, and improved
treatments.
22q11.2DS results from a hemizygous deletion on the long arm of chromosome 22 at
position 11.2 from the centromere, ranging in size from 0.5 megabases (Mb) to 3.0 Mb, with
the most common deletion sizes being 1.5 Mb and 3.0 Mb. The deletion encompasses between
30 and 90 known genes (Carmel et al., 2014; Jonas et al., 2014; Karayiorgou et al., 2010;
McDonald-McGinn et al., 2015; Qin et al., 2020). Symptoms of this disorder affect numerous
organs and systems, requiring a multidisciplinary approach for treatment. Moreover, children
with 22q11.2DS are at high-risk for developing serious psychiatric disorders in young adulthood
1

including schizophrenia spectrum disorder and other psychiatric disorders (Jonas et al., 2014;
Morrow et al., 2018).

History
Chromosome 22q11.2DS made its first appearance in clinical literature in the 1950s
(Fernandez et al., 2015). However, at that time it was not cohesively recognized as a defined
syndrome. It was not until the 1960s, when clinical groups started to define syndromes based
on their different observations of their patients, that it became a known syndrome (Fernandez
et al., 2015). In 1965, Dr. Angelo DiGeorge, a pediatric endocrinologist who treated children
with immunological and endocrine deficiencies, found that in children with this condition the
thymus and parathyroid glands were either absent or had severe hypo-plasticity (Fernandez et
al., 2015). DiGeorge also observed a disruption in the development of the third and fourth
branchial arches (Fernandez et al., 2015). Immunodeficiencies, hypoparathyroidism, and
congenital heart defects later became known as the triad of symptoms for DiGeorge syndrome
(McDonald-McGinn et al., 2015).
Around the same time, Robert Shprintzen, a speech-language pathologist, was treating
individuals with hyper-nasal speech, learning disabilities, cardiac malformations, submucosal or
overt cleft palate, poor fine motor control and craniofacial anomalies (Fernandez et al., 2015).
In the 1970s, the condition associated with these symptoms was referred to as Shprintzen
Syndrome or Velocardiofacial Syndrome (VCFS). With the advance of genetic technologies, it
became apparent that there were multiple syndromes that had the same underlying cause as
DiGeorge syndrome.
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In the early 1990s, Scambler, a biochemist and molecular geneticist, and Driscoll, a
medical and clinical geneticist, found a microdeletion on the long arm of chromosome 22 that
was present in most of the cases of DiGeorge syndrome (Fernandez et al., 2015). This discovery
became possible with the development of fluorescence in situ hybridization (FISH). FISH uses
probes with a fluorescent tag that binds to the sequence when there is a high degree of
complementarity. If the probe shows up on only one of the homologous chromosome 22
copies, one can infer the individual has the deletion. After this discovery, it was found that
there were numerous seemingly unconnected conditions that had underlying features that
were caused by this deletion on chromosome 22 (McDonald-McGinn et al., 2015). These
syndromes include Velocardiofacial Syndrome (Bassett & Chow, 2008; Fernandez et al., 2015;
Rozas et al., 2019), Conotruncal Anomaly Face Syndrome, DiGeorge Syndrome, Sphrintzen
syndrome, and a subset of patients with Optiz G/BBB and Cayler cardiofacial syndrome
(Hacıhamdioğlu et al., 2015; Karayiorgou et al., 2010; McDonald-McGinn et al., 2015; Morrow
et al., 2018). Since there are numerous syndromes with the same deletion, 22q11.2DS is
considered an umbrella term encompassing multiple conditions. Today, a diagnoses of
DiGeorge syndrome is reserved for the rare patients that have immunodeficiencies,
hypoparathyroidism, and congenital heart defects but do not have the deletion on
chromosome 22 (McDonald-McGinn & Sullivan, 2011).

Epidemiology
The frequency of 22q11.2DS ranges from 1:2,000 to 1:6,000 live births. The prevalence
of 22q11.2DS in fetuses is 1:1,000 (McDonald-McGinn et al., 2015; Morrow et al., 2018). The
true incidence of this disorder is undoubtedly higher due to underdiagnosis and misdiagnosis of
3

individuals. The prevalence of 22q11.2DS across sex and racial groups appears to be similar.
However, non-white patients may be diagnosed less frequently due to fewer detectable
craniofacial features observed in these populations (McDonald-McGinn & Sullivan, 2011). This
could also be due to socioeconomic status and access to quality healthcare. 22q11.2DS is
thought to be more widespread than reported and underrecognized because of the inherent
clinical unpredictability and heterogeneity that the disorder presents (Hacıhamdioğlu et al.,
2015).
The majority (90-96%) of patients diagnosed with 22q11.2DS have a de novo deletion,
meaning that neither parent has the deletion, with approximately 4 to10% of cases inherited
from an affected the parent (Bassett & Chow, 2008; Chen et al., 2004; Fernandez et al., 2015;
Jonas et al., 2014; McDonald-McGinn et al., 2015; Zinkstok et al., 2019). Individuals that have
22q11.2 deletion syndrome have about a 50% risk of passing the deletion on to their offspring
(Campbell et al., 2018). In de novo cases, the deletion likely occurred during gametogenesis,
most likely during meiosis (Bassett & Chow, 2008; Fernandez et al., 2015).

Symptoms
Symptom expressivity and severity in 22q11.2 is heterogeneous and can shift with age.
This complexity adds to the challenge of an accurate diagnosis of 22q11.2DS, as the
symptom(s), or the system(s) affected, are often the focus, instead of a holistic treatment
approach recognizing that new associated problems can arise from infancy through adulthood.
There are over 180 possible symptoms associated with this deletion syndrome (Gothelf, 2007;
Robin & Shprintzen, 2005). The syndrome has been shown to impact almost every organ,
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system, and developmental process (Hacıhamdioğlu et al., 2015; Shprintzen, 2008).
Manifestations of 22q11.2DS include skeletal abnormalities, distinct facial features, nervous
system irregularities, genitourinary anomalies, gastrointestinal problems, endocrine
abnormalities, heart defects, and developmental delays (Fernandez et al., 2015; McDonaldMcGinn et al., 2015; McDonald-McGinn & Sullivan, 2011). Behavioral problems, cognitive
disorders and psychiatric illnesses are also commonly observed in individuals with 22q11.2DS.
Anxiety disorders are common in people with 22q11.2DS and a 25-fold increased risk of
developing schizophrenia, relative to the general population (Coman et al., 2010; Fernandez et
al., 2015; Gothelf et al., 2005; McDonald-McGinn et al., 2015; McDonald-McGinn & Sullivan,
2011; Zinkstok et al., 2019).

Stress, Behavior and Psychological Aspects in 22q11.2DS
Stress is defined as any change from homeostasis resulting from internal or external
changes, demands, or threats. Stress can present with physical, mental, and/or emotional
aspects. Changes in hormonal activity as part of the coping and stress-response system are one
way of non-invasively measuring state and trait responses to stress. They can also provide
insight into the flexibility and efficacy of the stress response. Hormone levels that change in
response to stress and activation of the slower response hypothalamic-pituitary-adrenal
cortical (HPA) system can be accurately measured in saliva and include cortisol and
dehydroepiandrosterone (DHEA). Alpha amylase is a salivary enzyme that can serve as a proxy
measure of the faster response, sympathetic-adrenal-medullary (SAM) system. Stress is an
extremely common trigger for the emotional experience of anxiety and chronic stress can lead
to anxiety and other mental disorders. Anxiety can also elicit a potent physiological stress
5

response. The differences between stress and anxiety are that stress is external and ends after
the concern has passed, while anxiety is internal and persists after the concern is no longer
relevant. People with 22q11.2DS cope with a variety of stressors from birth through adulthood
related to serious medical problems and treatment, behavioral difficulties, and comorbid
psychological conditions that interfere with socioemotional and educational development.
Moreover, they may have poorer stress-coping abilities than age-matched peers. The
physiological effects of stress have been shown to contribute to risk of developing
schizophrenia in people without 22q11.2DS and thus, anxiety and stress may contribute to the
etiopathology of schizophrenia seen in individuals with 22q11.2DS (Armbruster et al., 2012;
Beaton & Simon, 2011; Stefanis et al., 2007; E. Walker et al., 2008; E. F. Walker & Diforio, 1997).

Low Copy Repeats
Low Copy Repeats (LCR) are areas in the genome that are almost identical to each other.
They are large blocks that have repetitive DNA sequences and often contain duplicated
pseudogenes. These areas are highly susceptible to chromosomal rearrangements like nonallelic homologous recombination (NAHR). This arises during meiosis and is the result of an
error in the regular process of recombination (Fernandez et al., 2015). Deletions and
duplications happen due to this inappropriate splicing of the DNA within the LCRs. The deleted
region on chromosome 22 contains four LCRs (LCR22A-LCR22D). The most common
recombination transpires between LCR22A and LCR22D, producing the 3.0 Mb deletion that is
observed in about 85% of individuals (Fernandez et al., 2015). A recombination between
LCR22A and LCR22B causes the 1.5 Mb deletion (Du et al., 2020; Morrow et al., 2018) which is
nested within the 3.0 Mb deletion (Fernandez et al., 2015). Very few individuals have a deletion
6

between LCR22B and LCR22D or LCR22C and LCR22D, which are typically not detected by FISH.
The high level of homology between LCR22A and LCR22D explains why a deletion caused by
recombination between these two repeats is particularly common (Morrow et al., 2018).
Since typically developing individuals have two homologous copies of each gene, a
mutation in one copy often has a small effect, if any. These individuals can rely on the
nonmutated copy to compensate and produce (in the case of genes encoding enzymes) the
normal enzymatic effect of the gene. Since individuals with 22q11.2DS have only one copy of
between 30 and 90 known genes, a mutation in one of these genes is more likely to have a
stronger effect and may alter enzymatic activity to an extent that is clinically significant.

Genes in the Deleted Region Related to Stress and Anxiety
The two genes that were selected for this study are catechol-O-methyltransferase
(COMT) and proline dehydrogenase (PRODH). Allelic variation in these genes have been shown
to relate to measures of stress and anxiety in other populations and in people with 22q11.2DS.
Catechol-O-methyltransferase (COMT) is responsible for degrading catecholamines like
dopamine, epinephrine (adrenaline), and norepinephrine (noradrenaline) in the brain and
periphery (McDonald-McGinn & Sullivan, 2011; Motahari et al., 2019). While there are multiple
Single Nucleotide Polymorphisms (SNPs) located within this gene, this study focuses on the SNP
at position 158 (rs4680). This SNP is a missense mutation that causes a change from a guanine
to an adenine and results in a change in amino acid from a valine to a methionine. A 40-50%
reduction of enzymatic activity is seen in the minor allele (methionine variant) of this gene
(Carmel et al., 2014; Zinkstok et al., 2019). This decrease in enzymatic activity causes a buildup
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of catecholamines within the synapse because they are not degraded as quickly. Epinephrine is
part of the rapid sympathetic autonomic stress response. Dopamine and norepinephrine, plays
a crucial role in the modulating the effects of anxiety (Zarrindast & Khakpai, 2015). Thus, an
increase in its concentration, due to a decrease in degradation, could alter the perception of or
response to stress or anxiety.
The proline dehydrogenase (PRODH) gene encodes an enzyme that converts proline to
glutamate, the main excitatory neurotransmitter in the central nervous system (Bender et al.,
2005; Carmel et al., 2014; Zinkstok et al., 2019). While there are a multitude of SNPs located
within this gene, this study focuses on the SNP located at position 185 (rs4819756). A change in
the nucleotides from an adenine to a guanine results in a change of amino acid from an arginine
to a tryptophan. A 30-70% enzymatic reduction of the PRODH gene is seen in individuals with
the tryptophan variant (Bender et al., 2005). This reduction of the PRODH enzyme is known to
cause hyperprolinemia, a buildup of proline. The buildup of proline leads to a reduction of
glutamate since the proline is not being converted to glutamate. This reduction of glutamate is
known to cause an increase in anxiety-like behaviors and stress (Kraal et al., 2020).
Both the COMT and PRODH genes are found in the region that is deleted in people with
22q11.2DS. As the deletion is hemizygotic, allelic variation in non-deleted copies of these genes
has a strong effect on the enzymatic activity of their products and the outcome of any other
genes that they interact with in their pathway. The role of these genes in the anxiety and
stress/coping response and risk for psychiatric disorders is well characterized (Carmel et al.,
2014; Coman et al., 2010; Gothelf et al., 2005; Morrow et al., 2018; Motahari et al., 2019;
Zinkstok et al., 2019)) and may contribute to greater risk and poorer stress-coping responses
8

contributing to risk of developing psychosis later in life in people with 22q11.2DS (Beaton &
Simon, 2011). Along with self-reported measures of stress and anxiety, physiological measures
of stress in the form of salivary hormones can be an important corroborative metric.

Stress Hormones
Cortisol is a glucocorticoid hormone that is produced by the adrenal cortex, involved in
metabolic and immunological regulation at rest and in response to stress. In most cases,
cortisol levels increase in response to a stressor and then return to baseline levels after
resolution of the stressor. Changes in cortisol can be accurately measured in blood or noninvasively from saliva samples, and salivary cortisol is a useful proxy measure of the
hypothalamic-pituitary-adrenocortical (HPA) stress response (Hellhammer et al., 2009; Speer et
al., 2019). Both short- and long-term stress responses are mediated by cortisol and enable
homeostasis to be maintained by making physiological and behavioral adjustments (Kamin &
Kertes, 2017). Extended bouts of chronic stress cause the body to keep producing stress
hormones and can lead to anxiety disorders (McEwen, 2004)
The actions of cortisol are offset by another hormone, dehydroepiandrosterone (DHEA),
which is also synthesized by the adrenal gland, and de novo in neurons and glia. DHEA appears
to be dysregulated in anxiety and mood disorders (Sripada et al., 2013). DHEA plays a role in
facilitating both short- and long-term stress responses/coping and play a role in the return to
homeostasis after the stressor has passed (Joseph & Whirledge, 2017; Kamin & Kertes, 2017).
A third salivary marker of an elevated SAM stress response alpha amylase. This enzyme
breaks down carbohydrates in saliva as part of initial digestive activity. An increase in
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autonomic nervous system activity in response to a stressor is associated with an increase in
alpha amylase concentrations (Akiyoshi et al., 2011; Ali & Nater, 2020). Alpha amylase is a
measure of stress that is not controlled by the hypothalamic-pituitary part of the HPA axis.
However, alpha amylase can be a corroborative measure of SAM activity and stress even if the
HPA system is dysregulated (Ali & Nater, 2020).

Stress, Psychological Measures and Genetics in 22q11.2DS
Genetic variation contributes to psychological and behavioral symptoms as well as
physiological measures of stress in salivary samples. However, a complicating factor is that
genes are part of networks and have multiple functions and interactions with other genes.
Physiological measures of stress are important for the following reasons:
1) These measures provide more nuanced biomarkers less dependent upon self-report for risk
of later problems.
2) Physiological tests yield insight into potential mechanisms (etiopathology). For example, they
allow us to address the question of whether having a specific variant of a gene increases stress
and allostatic load (long term wear and tear on the body due to chronic stress exposure),
leading to poorer coping skills.
3) 22.q11.2DS is a highly heterogenous disorder, and the consideration of multiple variables,
including hormonal measures, may help researchers identify subgroups within the population
of children with the deletion.
While the primary aim of this study was to measure allelic variation in COMT and
PRODH in relation to a reported measure of anxiety, in our post hoc analysis we considered a
10

range of behavioral and psychological metrics as well as physiological measures of stress
hormones in saliva, examining the results of Behavioral Assessment Scale for Children 2nd
edition (BASC-2) and Wechsler Intelligence Scale for Children 4th (WISC-IV) psychological
assessments. The T-scores of hyperactivity, aggression, conduct disorders, anxiety, depression,
somatization, atypical, withdraw, attention problems, adaptability, social skills, leadership,
activities of daily living, and functional communication from the BASC were used in this project.
(The T-score is a way to standardize and compare scores.) From the WISC-IV, verbal
comprehension, processing speed, perceptional reasoning, and working memory were studied.

Current Study
The aims and hypotheses or the current study are:

Aim 1
To measure allelic variation in the COMT gene in children and adolescents with 22q11.2DS and
assess its relationship to levels of anxiety (reported by their parents using a standardized test)
and to levels of stress indicators in saliva

Hypothesis 1.1
Individuals with the less active methionine (minor allele) enzyme variant of the COMT gene will
have a higher level of anxiety than individuals with the valine variant of the COMT gene.
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Hypothesis 1.2
Individuals with the less active methionine (minor allele) enzyme variant of the COMT gene will
have higher levels of cortisol, DHEA, and amylase in saliva samples, reflecting greater anxiety
than in individuals with the valine variant of the COMT gene.

Aim 2
To measure allelic variation in the PRODH gene in children and adolescents with 22q11.2DS and
asses its relationship to levels of anxiety (reported by their parents using a standardized test)
and to levels of stress indicators in saliva

Hypothesis 2.1
Individuals with the less active tryptophan (minor allele) variant of the PRODH gene will have a
higher level of anxiety than individuals with the arginine variant of the PRODH gene.

Hypothesis 2.2
Individuals with the less active tryptophan (minor allele) variant of the PRODH gene will have
higher level of cortisol, DHEA, and amylase in saliva samples, reflecting greater anxiety than
individuals with the arginine variant of the PRODH gene.

Aim 3
To assess the combined effects of allelic variation in the COMT and PRODH genes on levels of
anxiety (reported by their parents using a standardized test) and levels of stress indicators in
saliva.
12

Hypothesis
Individuals with minor alleles of both the COMT and PRODH genes will have elevated anxiety.

Hypothesis 3.2
Individuals with the minor alleles of both the COMT and PRODH genes will have higher level of
cortisol, DHEA, and amylase in saliva samples.

Materials and Methods
Participants
Participant recruitment and sample collection have been described previously (Sanders
et al., 2018). Briefly, participants were recruited via chromosome 22q11.2DS support groups
including the Louisiana 22q Support Network, social media (e.g., Twitter and Facebook), fliers
posted around the New Orleans area, and word-of-mouth. Upon arrival, families were briefed
on all tasks and procedures to be conducted and gave informed consent of the procedures.
Children signed agreement forms to indicate that they understood and wanted to continue with
the study.
Participants were children aged 7 years 10 month to 18 years 1 month (M = 12 years
and 5 months, SD = 2 years, and 6 months). Of the participants 43.3% were females and 56.7%
were males. Most participants were Caucasian (73.4%), while the remainder were identified by
their parents as Hispanic (10%), African American (3.3%) or not specified (13.3%). The presence
of a 22q11.2 deletion was confirmed by fluorescence in situ hybridization (FISH). Participants
were excluded if they had a history of head injuries, central nervous system infections, and
13

other focal neurologic abnormalities. This research was approved by the Institutional Review
Board at the University of New Orleans.

Sample Collection
Blood Sample Collection
The collection of whole blood was previously described (Sanders et al., 2018). Briefly,
blood was drawn by a trained phlebotomist at Touro Imaging Center (New Orleans, Louisiana)
into blood collection tubes with ethylenediaminetetraacetic acid (EDTA) and/or serum
separator tube (SST). The samples were then brought back to the Stress, Cognition, and
Affective Neuroscience (SCAN) laboratory at the University of New Orleans Psychology
Department. They were then centrifuged to remove the plasma/serum (which was aliquoted
into microcentrifuge tubes) and the blood cells were kept in the collection tube. Serum and
blood cells were placed in the -80°C freezer and frozen until the extraction was performed.

Saliva Collection
The collection of saliva samples was previously described in (Sanders et al., 2018). In the
afternoon, the participants were given a cognitive task designed to induce mild stress and five
saliva samples were collected. The times of collection were as follows: 1) following giving
consent and prior to beginning the tasks, 2) prior to beginning a mildly stressful cognitive task
3) after the mildly stressful cognitive task and prior to a second mildly stressful task, 4) after the
second mildly stressful cognitive task, and 5) after a recovery period of 15 min. Participants
passively deposited saliva into a 2 ml microcentrifuge tubes. Samples were then immediately
frozen and stored at -80 °C until further use.
14

DNA Extraction
Blood DNA Extraction
The Qiagen DNA Mini and Blood Mini kit was used to extract DNA from 200 µl of whole
blood cells following the manufacturer’s directions with a few adjustments. The samples were
incubated at 55°C (our incubator limit) for 10 mins instead of at 56°C. After Buffer AW2 was
centrifuged, the recommended step of placing the column in a new collection tube and
centrifuging it again was performed. Then, Buffer AE was incubated on the column at room
temperature for 5mins instead of 1 min as in the directions. The concentration of the sample
was measured using a Qubit fluorometer.

Saliva DNA Extraction
Most of the saliva samples that were used for extraction were from the fifth measure,
which was after the recovery period (disussed above). The Qiagen DNA Mini and Blood Mini kit
was used to perform DNA extractions on the saliva samples. The same adjustments were made
for the extraction of DNA from the saliva along with only 100 µl of Buffer AE being used instead
of 200 µl. The concentration of the sample was measured via Qubit.

Polymerase Chain Reaction
COMT Allele
The region surrounding the SNP in the COMT gene was amplified using polymerase
chain reaction (PCR). Since the concentration of the samples was known prior to PCR, the
volume of sample added to the reaction was adjusted to make the concentration of the DNA in
the reactions the equal (400 ng of DNA). The primers used for PCR were created to amplify a
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PCR product length of 316 base pairs. The following forward and reverse primers were used: 5’CAACCCTGCACAGGCAAGA-3’ and 5’-TTTCAGTGAACGTGGTGTGAAC-3’. Initial denaturation took
place at 95°C for 3 mins. DNA was then amplified in 34 cycles of 95°C for 30 s, 66°C for 30 s,
74°C for 1 min. The final extension step was at 72°C for 5 mins. The samples were then
observed on a 1% agarose gel that ran for 1 h at 70 v in 1x TEA buffer. The migration of PCR
products was compared against a 1 kb DNA ladder to confirm amplicon size.

PRODH Allele
PCR was used to amplify a 218 base pair region around the SNP in the PRODH gene. The
volume of sample added to the PCR reaction was adjusted to control the concentrations of the
samples. PCR reactions were carried out with the following forward and reverse primers: 5’CTTGGCCTCATTGGCGTAGA-3’ and 5’-GCAAGGCCACTATGCTTGCA-3’. The preliminary
denaturation occurred at 95°C for 1 min. Amplification involved 34 cycles of 95°C for 20 s, 55°C
for 20 s and 68°C for 15 s. The concluding extension step was at 68°C for 5 mins. A 1% agarose
gel was run for 1 h at 70 v in 1x TEA to examine the presence of samples sizes. The migration of
PCR products was compared against a 1kb DNA ladder to confirm amplicon size.

DNA Purification
The QIAquick PCR Purification kit from Qiagen was used to purify the samples. The
remaining volume of the PCR reaction was added to the column. Buffer PB was added at five
times the volume of the PCR reaction. Buffer PB contains a pH indicator, and if the liquid was
not a light yellow in color, 10 μl of sodium acetate was added to correct the pH. The column
was then centrifuged at 13,000rpm for 1 min and the flowthrough was discarded. Then 750 μl
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of buffer PE was pipetted onto the column and centrifuged again at 13,000rpm for 1 min. The
flowthrough was discarded and then the column was centrifuged at 13,000rpm for 1 min. After
this, the column was then placed in a microcentrifuge tube. Water that had been heated to
65°C was then pipetted onto the column and incubated at room temperature for 2 mins.
Finally, the column was centrifuged at 13,400rpm for 90 sec. The column was discarded, and
the concentration of the sample was examined via Qubit.

DNA Sequencing
A 20 mM primer solution (in TE) was made for each of the forward and reverse primers.
In the Premixed Simpleseq sequencing tubes, 6 μl of the DNA sample and 4 μl of the primer
solution were added for whole blood PRODH samples while 5 μl of the DNA sample and 5 μl of
the primer solution were added for COMT samples (blood and saliva). For sequencing the
PRODH gene in the saliva samples, 10 μl of the DNA sample and 10 μl of the primer solution
were added to the sequencing tubes. This was done because these samples required the use of
power read technology for sequencing. (With the power read option, the samples were
processed twice, which explains why double the volume was added to these tubes). The tubes
were then mailed out to Eurofins for sequencing. The following day we received the sequencing
data, which we analyzed on UGENE where the sample was compared to the reference to see
which nucleotide was present at the location of the SNPs.

Behavioral Assessment System for Children 2nd edition
The Behavioral Assessment System for Children (BASC) 2nd edition (Reynolds, 2010) is a
105-165 (age dependent) questionnaire that is used to measure changes in the child’s behavior
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and emotional status. The BASC, a parent report, is a multidimensional questionnaire that
parents fill out and is used to assess adaptive and problem behaviors in individuals ages 2-25
years old. The results of the BASC are split into four domain scores (adaptive skills,
externalizing, internalizing, and behavioral symptoms index) and fourteen subscale scores
including hyperactivity, aggression, conduct disorders, anxiety, depression, somatization,
atypical, withdraw, attention problems, adaptability, social skills, leadership, activities of daily
living, and functional communication.

Wechsler Intelligence Scale for Children- Fourth Edition
The Wechsler Intelligence Scale for Children 4th Edition (WISC-IV) (Gomez et al., 2016) is
a cognitive ability assessment of verbal comprehension, perceptual reasoning, working
memory, and processing speed. Composite scores are reported to have good internal
consistency (α = 0.88) and good test-retest reliability (α = 0.80). Inter-rater reliability is
excellent (α = 0.98). For this study, the WISC-IV was used to analyze verbal comprehension,
processing speed, perceptional reasoning, and working memory, which make up full-scale
intelligence quotient (FSIQ), in relation to the allelic variation.

Salivary Hormone/Enzyme ELISA
The stored saliva samples were assayed for cortisol, alpha amylase, and DHEA using
Salimetrics standardized and well-validated enzyme-linked immunosorbent assay (ELISA) kits
and were run in duplicate by the SCAN laboratory (Sanders et al., 2018). Cortisol and alpha
amylase were measured in μg/dL, while DHEA was measured in ng/ml.
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Statistical Analysis
Prior to analysis, all variables were screened for missing data and outliers. All statistical
analysis was carried out using IBM SPSS Statistics version 23.

Results
Statistical Analysis
The samples were separated into groups based on the alleles of the individual genes:
the COMT gene had 21 participants with the major allele and 9 with the minor allele. The
frequency of the minor allele in these participants is 0.3, which is close to the frequency in the
general population as reported in the National Center for Biotechnology Information (NCBI)
(approximately 0.4). There are roughly equal numbers of males and females within the COMT
major group, with 9 males and 11 females. The PRODH gene had 4 participants with the minor
allele (26 with the major allele) giving a frequency of 0.13, far less than was expected based on
the NCBI report (approximately 0.35). This discrepancy observed in the frequency of the minor
alleles is probably a stochastic result of the small sample size available in this study. The small
number of participants with the PRODH minor allele prevented us from carrying out any
meaningful statistical PRODH analyses. Thus, no further analyses were conducted using the
PRODH data. Demographic data for participants, sorted by SNP, are seen in Appendix 1 and 2.
The samples were divided into two groups according to the COMT allele. An
independent t-test comparing the standardized anxiety subscales from the BASC-2 parent
reports was performed. The independent sample t-test of the COMT gene determined that
individuals with the major allele (high enzymatic activity) had a higher anxiety T-score when
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compared to individuals with the minor allele (low enzymatic activity) [t (25) =2.36. p=0.021;
Glass’s delta effect size =0.69]. These findings are illustrated below in Figure 1.

Anxiety
75

* p=0.021

BASC2 T-scores (±SEM)

70
65
60
55
50
45
Major Allele G (n=21)

Minor Allele A (n=9)

COMT Allelic Variation

Figure 1: Allelic variation within the COMT gene and BASC-2 Anxiety T-Scores. The * indicates the p value for the ttest. There are 21 individuals with the major allele (high enzymatic activity) of the COMT gene and 9 individuals
with the minor allele (low enzymatic activity) of the COMT gene.

After testing our primary COMT hypothesis (a comparison of anxiety levels in the two
allelic groups), a series of independent t-tests were conducted on salivary stress indicators. The
salivary hormones and enzyme measures were log-transformed to normalize the data. The
stress hormone DHEA and enzyme alpha amylase measures were significant using t-tests that
were not corrected for multiple comparisons (p-values of 0.021 and 0.026, respectively),
cortisol was not significant either way. However, the differences between means for these
stress indicators were not significant after a Bonferroni correction. A Levene’s F-test
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determined that group variance was not equal with all p values being greater than 0.05. The
salivary cortisol measures did not differ between groups [t(13)=0.568. p=0.58; Glass’s delta
effect size =0.24]. This result is seen in Figure 2.

Log Cortisol Levels
Salivary Cortisol Levels (±SEM) ug/ml

2.00

1.80

1.60

1.40

1.20

1.00
Major Allele G

Minor Allele A

Allelic Variation

Figure 2: Allelic Variation within the COMT gene and Salivary Cortisol levels. This graph shows the log transformed
data. There are 21 individuals with the major allele (high enzymatic activity) of the COMT gene and 9 individuals
with the minor allele (low enzymatic activity) of the COMT gene.

The alpha amylase measures were log transformed before any further analysis. The
independent sample t-test of the COMT gene determined that individuals with the minor allele
(low enzymatic activity) had a higher salivary level of alpha amylase [t (26) =-2.366. p=0.026;
Glass’s delta effect size =0.67]. The mean for the alpha amylase of the major allele is 6.1453
(Std. Error Mean -1.0083) compared to 6.8212 (Std. Error Mean -1.11964) for the minor allele
as seen in Figure 3.
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LogAlphaAmylase
Salivary Alpha Amylase (±SEM) ug/dl
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Major Allele G

Minor Allele A

COMT Allelic Variation

Figure 3: Allelic Variation within the COMT gene and Salivary Alpha Amylase Levels. This graph shows the log
transformed data. There are 21 individuals with the major allele (high enzymatic activity) of the COMT gene and 9
individuals with the minor allele (low enzymatic activity) of the COMT gene.

Uncorrected independent t-tests indicated that DHEA levels were higher in children with
the minor allele. However, the difference between means for the salivary DHEA levels were not
significant after Bonferroni correction DHEA [t (22) =-2.312 p=0.031; Glass’s delta effect size
=0.73]. For the salivary DHEA measures, the mean of the major allele is 3.6526 (Std. Error Mean
-0.62264) compared to the minor allele which is 5.5004 (Std. Error Mean -0.59822) as seen in
Figure 4.
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LogDHEA

Salivary Hormone Measures (±SEM) ng/ml
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Figure 4: Allelic Variation within the COMT gene and Salivary DHEA Levels This graph is showing the log
transformed data. There are 21 individuals with the major allele (high enzymatic activity) of the COMT gene and 9
individuals with the minor allele (low enzymatic activity) of the COMT gene.

Because we found variation within the COMT groups with regards to anxiety and
salivary stress response indicators, and this population is heterogenous in symptom
presentation, we used Principal Component Analysis (PCA) to investigate factors that may be
affected by the differences between the COMT variants. This post hoc PCA analysis focused on
group differences by examining behavioral measures, and intelligence measures. The following
measures were included in the PCA analysis: WISC-IV (processing speed, perceptional
reasoning, working memory, and verbal comprehension) BASC-2 subscales (activities of daily
living, withdrawal, functional communication, conduct problems, aggression, somatization,
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depression, hyperactivity, leadership, social skills, attention problems, adaptability, and
atypicality). Four components with an eigenvalue greater than one explained 86.5% of the
variance and were maintained in the analysis. The loading value for each of the measures
(loading value of greater than +0.4 and less than -0.4 are significant) (Moody, 2015) are
displayed in Table 1. The PCA analysis revealed four main components that may indicate
different subgroups within the different measurements of this sample. After performing an
independent t-test to determine if the components differed depending on the allelic variation
of the COMT gene, no results were significant (all P values were greater than 0.05).
Table 1: Loading Values for each Measure within the Components. The Eigenvalues and percent variance for each
component are included.

Eigen Value
% Variance
Measurements
Activities of Daily Living
Processing Speed
Withdrawal
Functional Communication
Conduct Problems
Perceptional Reasoning
Aggression
Somatization
Depression
Hyperactivity
Leadership
Social Skill
Attention
Verbal Comprehension
Working Memory
Adaptability
Atypicality

Component 1
6.583
38.725

Component 2
3.481
20.477

Component 3
3.259
19.171

Component 4
1.388
8.165

0.806
0.770
0.702
0.693
-0.679
0.593
-0.263
0.301
-0.351
-0.317
-0.047
0.168
-0.551
0.241
0.055
-0.050
-0.199

-0.203
-0.044
-0.044
-0.221
0.556
0.109
0.937
0.877
0.760
0.510
0.097
-0.186
-0.151
-0.606
-0.072
-0.425
0.398

0.475
-0.130
-0.130
0.178
-0.132
0.355
0.007
0.205
-0.210
-0.502
0.965
0.915
-0.687
-0.609
-0.029
0.134
-0.410

-0.067
0.022
0.559
-0.564
0.164
0.459
0.065
0.066
0.154
0.491
-0.096
-0.172
0.365
-0.225
0.977
-0.846
0.723
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Table 2: Independent t-tests of PCA analysis

Component

Allelic Variation

Mean (SD)

Component 1

Major

-0.3886975(0.67) 0.308

Minor

.0000000(1.0)

Major

.0647736(0.99)

Minor

.0000000(1.0)

Major

.0143418(0.14)

Minor

.0000000(1.0)

Major

-.0843374(0.76)

Minor

.0000000(1.0)

Component 2

Component 3

Component 4

P value

0.873

0.970

0.825

Group composition analysis related to the PRODH gene variants indicated that only 4
individuals out of 30 had the minor allele. Therefore, we were unable to conduct further
analyses on this aspect of the experiment for both aim 2 and 3.

Discussion
Chromosome 22q11.2DS is a complex developmental disorder with a heterogenous
symptom presentation and uncertain developmental path, including very high risk of mental
illness in adulthood. The overarching aim of the present study was to better characterize
genetic factors that may contribute to this risk and affect quality of life, including anxiety,
causing a higher risk of developing mental illnesses (Angkustsiri et al., 2012). This deletion
syndrome has a wide variety of phenotypes that vary in severity among individuals, as well as
during the lifetime of a given individual, yet little is known about the relationship between the
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genes found on the homologous chromosome in the deleted region in 22q11.2DS and its
varying phenotypes – especially in relation to anxiety and the accompanying stress response.
COMT and PRODH are two genes that have been shown to be of interest in the development of
mental illness, including schizophrenia (Clelland et al., 2016; Fernandez et al., 2015; Gothelf et
al., 2005; Qin et al., 2020; Tunbridge et al., 2006; Zinkstok et al., 2019).
It was found in individuals with 22q11.2DS that the major COMT (high enzymatic
activity) allele had higher psychological anxiety when compared to individuals with the minor
(low enzymatic activity) allele (p-0.021). This is opposite of what we had hypothesized, but it
does match the findings from (Zarrindast & Khakpai, 2015), who found that dopamine depletion
is an inducer of anxiety. The depletion of dopamine would be caused by the high enzymatic
activity of the major (valine) allele of COMT gene. This is interesting because this allele is the
more common one within the general population. Both dopamine and norepinephrine are
catabolized by the COMT gene and are regulators of the HPA axis (Armbruster et al., 2012;
Feldman & Weidenfeld, 2004). Therefore, individuals with the minor (methionine) allele of the
COMT gene should have higher levels of norepinephrine and a stress response associated with
dysregulation of the HPA axis.
A further analysis was done to better characterize psychological and behavioral factors
that associated with COMT allelic variation. During this analysis, independent t-tests indicated
that the methionine (low enzymatic activity) allele of the COMT gene had elevated salivary
DHEA (p-0.031) and alpha amylase (p-0.026) but not cortisol levels. Chronic stress can result in
dysregulation of the HPA stress response system. 22q11.2DS is inherently stressful and this may
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contribute to risk of psychopathology and psychosis (Beaton & Simon, 2011; Joseph &
Whirledge, 2017; McEwen, 2004).
In the present study, some of the participants with the minor COMT variant
demonstrated an elevated SAM stress response as indicated by elevated AA but an attenuated
HPA stress response as indicated by lower cortisol but higher DHEA (though these results were
only significant prior to a Bonferroni correction). This seems paradoxical as normally lower
cortisol, but higher DHEA would be indicative of a robust coping response. However, it appears
that these individuals are demonstrating a dysregulated HPA response seen in other
populations with chronic stress. For example, adults with 22q11.2DS have been shown to have
low cortisol levels in response to daily stressors. Women with PTSD have also been shown to
have higher levels of DHEA and lower levels or cortisol indicative of HPA dysregulation (Gill et
al., 2008; Grillon et al., 2006; van Duin et al., 2019).
A PCA was performed to obtain an improved understanding of the behavioral and
intelligence measures within individuals that have 22q11.2DS. This divides the measures
including hyperactivity, aggression, conduct disorders, anxiety, depression, somatization,
atypical, withdraw, attention problems, adaptability, social skills, leadership, activities of daily
living, and functional communication from the BASC-2 and verbal comprehension, processing
speed, perceptional reasoning, and working memory from WISC-IV. The PCA results were not
significant.
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It appears that individuals with the major allele of the COMT gene are at a higher risk of
developing anxiety. The possibility that this could lead to an increased risk of developing other
psychotic disorders, including schizophrenia, should be examined more fully in future research.

Limitations
Limitations of this project include a small sample size. There were too few individuals
with the PRODH minor allele for a meaningful analysis. This study also only looked at two out of
the 35-90 known genes in the deletion. Symptoms that arise from such a complex and
heterogeneous disorder like 22q11.2DS are likely the product of many gene-gene interactions,
copy number repeats, and allelic variation of many other genes. Psychological anxiety was also
determined via parent report. While parents spend a great deal of time observing and
interacting with their children, they may not be privy to all the child’s psychology at a given
time. Another limitation is the wide age range of the sample. The difficulties, problems,
stressors, and coping skills that children possess will differ as they age.

Future Directions
Future directions should include a follow up with these participants to determine if they
develop any psychotic disorders. Other genes in the deleted region should also be looked at
independently and in conjunction to get a better understanding of how the genes interact with
each other and lead to the varying phenotypes seen in the deletion syndrome. This study would
also benefit from a larger sample size and/or a longitudinal study. A factor analysis should be
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done on these measures because clearly the FSIQ, processing speed, and functional
communication are correlated. Other measures of FSIQ should also be investigated.
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Appendices
Appendix 1 Demographics of COMT Allelic Variation

COMT Major
Age (Months)
147.24
Sex (% Male)
57.1%
Ethnicity (%)
Caucasian: 72.2
Hispanic: 95
African American: 4.8
Not Specified: 9.5
PRODH Major
19
PRODH Minor
2
Anxiety
65.95
Depression
62.57
Adaptability
39.67
Social Skills
41.43
Activities of Daily Living
34.52
Functional Communication 32.52
Adaptive Skills
34.14
Hyperactivity
63.52
Aggression
51.61
Conduct Problems
52.48
Externalizing
56.52
Internalizing
65.1
Atypicality
64.29
Withdrawal
66.33
Attention Problems
63.86
Behavioral Symptom Index 64.9
Leadership
35.33
Somatization
61.81
FSIQ
70.33
Verbal Comprehension
81.52
Processing Speeds
66.38
Perceptional Reasoning
75.1
Working Memory
71.81
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COMT Minor
153.89
55.6
Caucasian: 66.7
Hispanic: 11.1
African American: 0
Not Specified: 22.2
7
2
55.56
59
40.89
41.22
33.56
36.56
35.89
66
51.33
49.22
55.67
61.67
62.89
66.78
60.56
62.22
37.67
63.78
74.22
84.89
72.56
78
81

Appendix 2 Demographics of PRODH Allelic Variation

PRODH Major
Age (Months)
150.5
Sex (% Male)
53.8
Ethnicity
Caucasian: 73.1
Hispanic: 11.5
African American: 3.9
Not Specified: 11.5
COMT Major
19
COMT Minor
7
Anxiety
63.23
Depression
61.81
Adaptability
40.77
Social Skills
40.81
Activities of Daily Living
33.58
Functional Communication 33.85
Adaptive Skills
34.65
Hyperactivity
64.46
Aggression
52.11
Conduct Problems
51.77
Externalizing
56.65
Internalizing
64.04
Atypicality
63.58
Withdrawal
64.58
Attention Problems
63.27
Behavioral Symptom Index 64.5
Leadership
35.58
Somatization
62.04
FSIQ
71.19
Verbal Comprehension
83.46
Processing Speeds
70.35
Perceptional Reasoning
74.19
Working Memory
74.42
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PRODH Minor
141
75
Caucasian: 75
Hispanic: 0
African American: 0
Not Specified: 25
2
2
60.25
59.5
35.25
45
38.5
33
34.7
63
47.75
49.75
53.75
64.25
65.75
78.75
60.25
66
39
64.75
73.5
76.5
54.5
87.5
80.75

Appendix 3 PRODH Behavioral Measures

BASC-2 Measures

Behavioral Measures
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Appendix 2 PRODH Intelligence Measures

Intelligence Measures
100
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WISC-IV Measures
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Comprehension
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